A Phase I, Randomized, Placebo-Controlled, Dose Escalating Cross Over Study To Evaluate The Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of PF-05105679 Under Fasted Conditions In Healthy Volunteers.
Latest Information Update: 14 Jan 2020
At a glance
- Drugs PF 5105679 (Primary) ; Oxycodone
 - Indications Pain
 - Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
 - Acronyms SINGLE DOSE
 
Most Recent Events
- 30 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
 - 15 Jul 2011 New trial record